Evidence map›Paper›PMID 35039679›Full record

ReviewNature reviews. Clinical oncology2022

Harnessing big data to characterize immune-related adverse events.

Ying Jing, Jingwen Yang, Douglas B Johnson, Javid J Moslehi, Leng Han

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 5 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 5 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Observational
  9. A pharmacovigilance data-driven approach to reveal high fatal adverse events following checkpoint immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ying Jing *Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingwen Yang *Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA.
Douglas B JohnsonDepartment of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. douglas.b.johnson@vumc.org.ORCID http://orcid.org/0000-0002-6390-773X
Javid J MoslehiSection of Cardio-Oncology & Immunology, Division of Cardiology, Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA. Javid.Moslehi@ucsf.edu.
Leng HanCenter for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA. leng.han@tamu.edu.ORCID http://orcid.org/0000-0002-7380-2640
Prevention Institute · USShanghai Jiao Tong University · CNUniversity of California, San Francisco · USVanderbilt University Medical Center · US

Funding

Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9M
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3M
Long-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3M
NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021
6 · The paper itself

Abstract

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are associated with a unique spectrum of organ-specific inflammatory toxicities known as immune-related adverse events (irAEs). Given the expanding use of ICIs, an increasing number of patients with cancer experience irAEs, including severe irAEs. Proper diagnosis and management of irAEs are important to optimize the quality of life and long-term outcomes of patients receiving ICIs; however, owing to the substantial heterogeneity within irAEs, and despite multicentre initiatives, performing clinical studies of these toxicities with a sufficient cohort size is challenging. Pioneering studies from the past few years have demonstrated that aggregate clinical data, real-world data (such as data on pharmacovigilance or from electronic health records) and multi-omics data are alternative tools well suited to investigating the underlying mechanisms and clinical presentations of irAEs. In this Perspective, we summarize the advantages and shortcomings of different sources of 'big data' for the study of irAEs and highlight progress made using such data to identify biomarkers of irAE risk, evaluate associations between irAEs and therapeutic efficacy, and characterize the effects of demographic and anthropometric factors on irAE risk. Harnessing big data will accelerate research on irAEs and provide key insights that will improve the clinical management of patients receiving ICIs.

Indexed as

Big DataNeoplasmsHumansImmune Checkpoint InhibitorsQuality of LifeImmune Checkpoint Inhibitors

Identifiers

PMID35039679
OpenAlexW4205294804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.